What is the issue size of the Mankind Pharma IPO?

The issue size of the Mankind IPO is 4,00,58,844 equity shares that will be offloaded via Offer for Sale.

What are the open and close dates of the Mankind Pharma IPO?

The Mankind Pharma IPO dates are 25-27 APR 2023

How will I know when my Mankind Pharma IPO order is placed?

We will notify you when your order is successfully placed with the stock exchange.

What is the Mankind Pharma IPO price?

The Mankind Pharma IPO price is yet to be announced.

Who is the registrar of the Mankind Pharma IPO?

The registrar of the Mankind Pharma IPO is KFin Technologies Ltd.

Who are the Book Running Lead Managers of the Mankind Pharma IPO?

The Book Running Lead Managers of the Mankind Pharma IPO includes Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, IIFL Securities Ltd, Jefferies India Pvt Ltd, and JP Morgan India Pvt Ltd.

What is the face value of a share in the Mankind IPO?

Mankind Pharma has filed its DRHP with SEBI announcing a face value of Rs. 1 per equity share.

Mankind Pharma IPO

Mankind Pharma Ltd

₹13,338 /13 sharesMinimum Investment

Mankind Pharma IPO Listing DetailsListed OnIssue PriceListing PriceListing Gains
BSE & NSE₹1,080.00₹1,300.00₹220.00 (20.37%)
Mankind Pharma IPO DetailsBidding DatesMin. InvestmentLot SizePrice Range
25 Apr ‘23 - 27 Apr ‘23₹13,33813₹1,026 - ₹1,080
Issue SizeIPO Doc
4326.00CrRHP PDF
Subscription Status As on 27 Apr '23, 5:05 PMQualified Institutional Buyers
49.16x
Non-Institutional Investor
3.80x
Retail Individual Investor
0.92x
Total
15.32x
About Mankind PharmaMankind Pharma is a leading pharmaceutical and healthcare products company based in New Delhi. The company specializes in manufacturing and marketing condoms, antibiotics, gastrointestinal, cardiovascular, dermal, and erectile dysfunction drugs.
Started in 1991, Mankind Pharma today is India’s fourth largest pharmaceutical company in terms of domestic sales. The company is known for acute and chronic therapeutic medications. With an employee base of 22,000+ Mankind Pharma positions itself as a provider of affordable and accessible medicines. In addition to over-the-counter medicines and prescription drugs, Mankind Pharma also deals in FMCG products in India and overseas.;
Parent Organisation
Mankind Pharma Ltd
Founded
1991
Managing Director
Rajeev Juneja
Strengths & Risks
Here are some strengths of Mankind Pharma Limited:
Mankind Pharma is one of the largest domestic formulators in India. Its domestic sales make it the fourth largest pharma company in the country. The company is focusing on scaling domestic business further.
The company has a well-diversified portfolio of therapeutic medications that includes antibiotics, cardiovascular, gynecology, gastrointestinal vitamins, respiratory, anti-diabetic, dermatology, analgesics, and neuro medications.
The company has established a number of brands in the consumer healthcare segment with condoms, pregnancy detection, emergency contraceptives, supplements, among others that have a strong brand recall. 
Mankind Pharma has a wide market and distribution network along with a laser-sharp focus on affordable medicines.
Here are some risk factors associated with Mankind Pharma Limited:
The company’s overall financial performance depends on compliance to Government regulations and policies. Any deviance from Government regulations can hamper company operations and cash flows. 
The company has to regularly obtain, maintain, and renew regulatory approvals, which are often expensive. Failure to renew or get licenses and approvals can be a risk. 
It is difficult to accurately forecast the demand for certain products, which can result in inventory mismanagement, leading to an adverse effect on operations and cash flows.
Any delay or disruption in the raw material supply chain or products from third-party suppliers can result in an adverse impact on the pricing of the medications and products. An increase in the cost of raw materials can also be detrimental to sales.
The company relies on the effectiveness of its drugs and pharma products. If the drugs and products fail to yield the desired result, it can hamper the sales and bottomline. 
Counterfeit drugs being sold under Mankind Pharma’s branding can tarnish the company’s reputation and impact its sales. 
The company relies strongly on quality control when manufacturing and marketing drugs. Any lapse in quality control can also negatively impact business. 
There are outstanding legal proceedings against the company, its promoters, subsidiaries, and directors. Some of these include criminal and tax proceedings.
Financials
*All values are in Rs. Cr
No Graph Data To Display
Application detailsApply asPrice bandApply upto
Regular₹1026 - 1080₹2 Lakh
High Networth Individual₹1026 - 1080₹2 - 5 Lakh
For Mankind Pharma IPO, eligible investors can apply as Regular.

Listed On	Issue Price	Listing Price	Listing Gains
BSE & NSE	₹1,080.00	₹1,300.00	₹220.00 (20.37%)

Bidding Dates	Min. Investment	Lot Size	Price Range
25 Apr ‘23 - 27 Apr ‘23	₹13,338	13	₹1,026 - ₹1,080

Issue Size	IPO Doc
4326.00Cr	RHP PDF

Apply as	Price band	Apply upto
Regular	₹1026 - 1080	₹2 Lakh
High Networth Individual	₹1026 - 1080	₹2 - 5 Lakh

Vaishnavi Tech Park, 3rd & 4th Floor
Sarjapur Main Road, Bellandur
Bengaluru – 560103
Contact Us
PRODUCTS
StocksFutures & OptionsIPOMutual FundsCreditBill Payments
GROWW
About UsPricingBlogMedia & PressCareersHelp and Support
QUICK LINKS
AMC Mutual FundsCalculatorsGlossaryOpen Demat AccountGroww DigestSitemap
ⓒ 2016-2023 Groww. All rights reserved, Built with ♥in India

ABOUT GROWW

Groww is India’s growing financial services platform where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

NextBillion Technology Private Limited (CIN: U65100KA2016PTC092879) is a member of NSE & BSE with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - No.11, 2nd floor, 80 FT Road, 4th Block, S.T Bed, Koramangala, Bengaluru – 560034. For any grievances related to Stock Broking/DP, please write to [email protected] , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

NextBillion Technology Private Limited makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.